Target intelligence / Profile preview

Solute carrier family 26 member 2 (SLC26A2)

Target
SLC26A2
Molecular classification
Transporter, Anion exchanger, Membrane protein, Solute carrier
01

Overview

Solute carrier family 26 member 2 (SLC26A2) is a widely expressed cell membrane protein that functions primarily as an electroneutral sulfate/chloride antiporter, facilitating the uptake and exchange of inorganic sulfate and other anions across the plasma membrane[1][2][4]. It is crucial for the sulfation of proteoglycans, essential molecules for cartilage structure during development, and thus vital for normal cartilage and bone formation[4]. Pathogenic mutations in SLC26A2 severely disrupt proteoglycan sulfation, resulting in inherited skeletal dysplasias with phenotypes ranging from lethal achondrogenesis type 1B and atelosteogenesis type 2 to less severe diastrophic dysplasia and multiple epiphyseal dysplasia[1][2][3][4]. The gene is also implicated in non-congenital disease contexts such as Crohn’s disease (where expression is upregulated) and certain cancers (where repression promotes proliferation and TRAIL-resistance)[2]. SLC26A2 is considered an important therapeutic target, particularly in modeling and understanding the cellular defects in chondrodysplasia and exploring new therapies[1][2].

Other names
Sulfate transporterDTDDTDSTDiastrophic dysplasia proteindiastrophic dysplasia sulfate transporterD5S1708EDM4MST153MSTP157sulfate anion transporter 1
02

Biological functions

Sulfate transportProteoglycan sulfationCartilage developmentIon transportRegulation of bone growth
03

Disease associations

Congenital skeletal dysplasias (including diastrophic dysplasia, achondrogenesis 1B, atelosteogenesis type 2, recessive multiple epiphyseal dysplasia)Osteoporosis of long bonesCrohn’s disease (upregulated)Cancer (downregulated with increased proliferation and TRAIL resistance)
04

Safety considerations

Therapeutic challenge is severe, as loss of function causes lethal or severe skeletal abnormalitiesgene therapy or other interventions must address fundamental cartilage development defects
05

Biomarkers

Val341delc.1020_1022delTGTArg279Trp (R279W)Cys653Ser (C653S)

Beyond the preview

Go deeper on Solute carrier family 26 member 2 (SLC26A2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 26 member 2 (SLC26A2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call